Pharmacyte Biotech Inc (OTCMKTS:PMCB) reported that its treatments and technology will be featured on the popular ION Network and Discovery Channel on June 30, 2015. These two platforms are stated as a popular source for breaking and impressive technology. Consumer, health, entertainment, and travel news.
The technology will be covered in ION Network’s news magazine known as “NewsWatch” which airs countrywide in the United States and can be watched in almost every market throughout the nation. It is a significant new for Pharmacyte as through NewsWatch it would be able to reach over 96 million U.S. households.
So far, more than 700 million people have watched the NewsWatch series, including in the list of the booming and independently shaped news magazines on TV. The show will cover Pharmacyte’s story in “HealthWatch.” It is a dedicated segment that covers the latest medical innovations and newest medical advances, having a positive impact on health.
Pharmacyte’s CEO, Kenneth L. Waggoner, said that they have an impressive story, and when they were approached by NewsWatch to cover company’s technology and the treatments under development for diabetes and cancer to countrywide audience, they grabbed the opportunity. The mission of the company is to help people and this show provides one of the best ways to connect with people. The compelling story will air on two of the most-watched channels and can be seen by as many as 96 million households in the U.S.
NewsWatch series began in 1990, and since then it has covered over 10,000 independent stories on a wide range of topics, including celebrities, entertainment, public policy issues, new product introductions, medical breakthroughs, finance, travel, and numerous other topics.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) tried to reverse the intermediate down trend yesterday as it finished the first trading session of the week with a solid gain of 22.6%. The closing price of $0.1340 was almost the same with the day high at $0.01380, implying a lot of strength but the move also retraced the last phase of the decline completely, as it almost touched the last swing high of $0.14. That price action may invite a short term correction if not a total reversal. From a larger perspective, the long term range of $0.10-$0.27 may not be breached anytime soon.